SESSION TITLE: Airways 2
SESSION TYPE: Original Investigation Poster
PRESENTED ON: Wednesday, October 26, 2016 at 01:30 PM - 02:30 PM
PURPOSE: Randomized clinical trials have shown that QVA149, the combination of indacaterol 110 mcg and glycopyrronium 50 mcg, is effective in the management of patients with moderate to severe COPD. To date, there are no real-life Canadian studies evaluating its effectiveness in the management of symptomatic patients as monotherapy replacing tiotropium or fixed dose LABA/ICS. The POWER study addresses this need.